Biocartis’ Post

Revolutionize your NSCLC diagnostics with Idylla™ 🏆 ⏱️Speed up your therapy decisions for better patient outcomes! Test for EGFR, ALK, ROS1, RET, METex14 in only 3 hours and immediately start the right targeted therapy for >90% of your patients with first-line actionable biomarkers* 👉 Read more https://lnkd.in/e-qHZv8T Your patients, our priority. Guiding them to the right therapy within hours ⚡ #Idylla #Biocartis #GeneFusion #ALK #ROS1 #RET #METex14 #EGFR #LungCancer #NSCLC *Hendriks, L. E., et al. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 34(4), 339–357.

Revolutionize your NSCLC diagnostics with Idylla™ 🏆 ⏱️Speed up your therapy decisions for better patient outcomes! Test for EGFR, ALK, ROS1, RET, METex14 in only 3 hours and immediately start the right targeted therapy for >90% of your patients with first-line actionable biomarkers* 👉 Read more https://lnkd.in/e-qHZv8T Your patients, our priority. Guiding them to the right therapy within hours ⚡ #Idylla #Biocartis #GeneFusion #EGFR #LungCancer #NSCLC *Hendriks, L. E., et al. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 34(4), 339–357.

Test for EGFR, ALK, ROS1, RET and METex14 in ONLY 3 HOURS and immediately start the right targeted therapy for >90% of your patients with first-line actionable biomarkers*. IDYLLA™ FIRST. Guiding First-Line Therapy Decisions in NSCLC ⏱️ Learn more 👉🏻 https://lnkd.in/enNpBhir #Biocartis #Idylla #EGFR #GeneFusion #ALK #ROS1 #RET #METex14 #LungCancer #NSCLC *Hendriks, L. E., et al. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 34(4), 339–357.

Test for EGFR, ALK, ROS1, RET and METex14 in ONLY 3 HOURS and immediately start the right targeted therapy for >90% of your patients with first-line actionable biomarkers*. IDYLLA™ FIRST. Guiding First-Line Therapy Decisions in NSCLC ⏱️ Learn more 👉🏻 https://lnkd.in/enNpBhir #Biocartis #Idylla #EGFR #GeneFusion #ALK #ROS1 #RET #METex14 #LungCancer #NSCLC *Hendriks, L. E., et al. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 34(4), 339–357.

Continuing our quick look at published trials for novel therapy alternatives to radical cystectomy for BCG-unresponsive non-muscle-invasive bladder cancer.   4. Intravesical portuzumab monatox-qqrs (Vicinium)   Vicinium is a recombinant fusion protein that blocks protein synthesis in order to mediate tumour cell death. The FDA denied approval for its use in BCG-unresponsive non-muscle-invasive bladder cancer following a review of the results of a phase 3 single-arm clinical trial. The 3-month complete response rate was 40%, and 52% of patients who responded remained disease-free for 12 months after treatment.   Tomorrow: IL-15 superagonist + BCG   #medicalinnovation #bladdercancer #HIVEC #CombatMedical 

Merck Group & Kelun LifeSciences (Pvt)Ltd’s TROP-2 ADC could be a ray of hope post Phase III data readout highlighting its efficacy in the most aggressive breast cancer type, TNBC. Sacituzumab tirumotecan, known as SKB264, has demonstrated outstanding potential in the treatment of advanced triple-negative breast cancer (TNBC), substantially lowering the risk of disease progression or mortality while maintaining an acceptable safety profile. An interim analysis conducted on June 21, 2023, indicated that patients treated with SKB264 experienced a median progression-free survival (PFS) of 5.7 months, which is more than twice the 2.3 months observed in patients who received standard chemotherapy. The 6-month PFS rates further highlighted the difference, with SKB264 achieving a rate of 43.4% compared to 11.1% for chemotherapy. In patients exhibiting high TROP2 expression, the median PFS for SKB264 was 5.8 months, significantly longer than the 1.9 months for those on chemotherapy. DelveInsight Business Research LLP's American Society of Clinical Oncology (ASCO) 2024 Exclusive Coverage, Unlock the Best Expert Insights and Comprehensive Analysis @ https://lnkd.in/dmRMbVCf #ASCO24 #ASCO #ASCOconference #SacituzumabTirumotecan #SKB264 #AdvancedTNBCTreatment #CancerTherapyInnovation #ProgressionFreeSurvival #TROP2Expression #BreastCancerTreatment #OncologyBreakthroughs #ChemotherapyAlternatives #CancerSurvivalImprovements #TargetedCancerTherapy #TripleNegativeBreastCancer #CancerResponseRate #MedicalResearchAdvances  #HopeForCancerPatients #PersonalizedOncology #CancerTreatmentOptions

Continuing our quick look at published trials for novel therapy alternatives to radical cystectomy for BCG-unresponsive non-muscle-invasive bladder cancer.   4. Intravesical portuzumab monatox-qqrs (Vicinium)   Vicinium is a recombinant fusion protein that blocks protein synthesis in order to mediate tumour cell death. The FDA denied approval for its use in BCG-unresponsive non-muscle-invasive bladder cancer following a review of the results of a phase 3 single-arm clinical trial. The 3-month complete response rate was 40%, and 52% of patients who responded remained disease-free for 12 months after treatment.   Tomorrow: IL-15 superagonist + BCG   #medicalinnovation #bladdercancer #HIVEC #CombatMedical 

#HenliusMedicalHub 🌍 We are proud to announce that the Phase 2 study results of HLX07, an innovative anti-EGFR monoclonal antibody, have been published in Cancer Communications (Latest Impact Factor: 20.1)! 🎉 Currently, no #EGFR targeted therapies for advanced esophageal squamous cell carcinoma (#ESCC) have been approved globally. 📊 Key Findings from the Study: Combination Therapy (HLX07 + serplulimab + chemotherapy): ORR 60%, PFS 7.8 months, DOR 7.2 months. Monotherapy (HLX07): ORR 15%, PFS 1.5 months, DOR not reached (>6 months). HLX07 shows promising anti-tumor activity and controlled toxicity, providing hope for better treatment outcomes. Henlius is actively advancing Phase 2 trials for HLX07 across multiple indications, including ESCC, squamous cell carcinoma of the skin, and nasopharyngeal carcinoma. Together, we are working to deliver innovative and affordable therapies to patients worldwide. 💡 Learn more: https://lnkd.in/gdGW9Esq https://lnkd.in/giAmKWK6 #CancerResearch #Oncology #HealthcareInnovation #ClinicalTrials

This content is for US audiences only. #ASCO24 starts this week but we had some early-breaking good news on the lung front: we announced positive high-level overall survival results from the TROPION-Lung01 Phase III trial. Patients with advanced or metastatic NSCLC who had been previously treated with another therapy saw a clinically meaningful OS benefit with our treatment versus chemo.   Today’s readout isn’t the first encouraging data we’ve had for our our TROP2-directed antibody drug conjugate (ADC). As last year’s ESMO, we shared TROPION-Lung01’s benefits over chemo in improving progression-free survival in this patient population. Taken together, we believe in the possibility of an impactful TROP2-directed ADC in advanced lung cancer – and we’re pushing ahead with the research that will deliver this new treatment option to patients.   We’ll share the full results at an upcoming medical meeting. Learn more about today’s announcement: https://bit.ly/3WY4bk3   #USOnly #AstraZenecaUS

𝐅𝐃𝐀 𝐀𝐩𝐩𝐫𝐨𝐯𝐞𝐬 𝐏𝐞𝐫𝐢𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐯𝐞 𝐎𝐩𝐝𝐢𝐯𝐨® 𝐟𝐨𝐫 𝐑𝐞𝐬𝐞𝐜𝐭𝐚𝐛𝐥𝐞 𝐍𝐒𝐂𝐋𝐂! The U.S. FDA has approved Opdivo® (nivolumab) with chemotherapy for perioperative treatment of resectable non-small cell lung cancer (NSCLC), offering new hope for patients. This decision follows the success of the CheckMate-77T trial, showing a 42% risk reduction in recurrence and improved event-free survival. Opdivo is now the only PD-1 inhibitor to show significant benefits in both neoadjuvant and perioperative regimens for NSCLC. Bristol Myers Squibb 𝐋𝐞𝐚𝐫𝐧 𝐌𝐨𝐫𝐞:  https://lnkd.in/gtdfCFcS #opdivo #fdaapproval #lungcancer #immunotherapy #oncology #bristolmyerssquibb #cancercare #perioperativetreatment #cancerresearch #checkmate77t #pharma #healthcare #lunghealth #innovation #NSCLC